Mucormycosis Market

Market Overview:

The 7 major mucormycosis markets reached a value of USD 1,166.0 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,069.3 Million by 2035, exhibiting a growth rate (CAGR) of 9.21% during 2025-2035.

The mucormycosis market has been comprehensively analyzed in IMARC's new report titled "Mucormycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Mucormycosis, also known as black fungus, is a life-threatening but rare fungal infection due to molds in the order Mucorales, such as Rhizopus, Mucor, and Lichtheimia species. It usually occurs in those with compromised immune systems, for example, uncontrolled diabetes, cancer, organ transplant, or long-term corticosteroid therapy. The infection is usually contracted by inhaling fungal spores in the environment, which develops into pulmonary or rhino-orbital-cerebral mucormycosis. It may also gain entry into the body via cuts or burns, which infect the skin, or when taken orally, it can infect the gastrointestinal tract. The disease is rapidly progressive, with tissue necrosis resulting from the invasion of blood vessels by the fungi, resulting in thrombosis and compromised blood supply to the infected areas. The early signs vary with the location of infection and can include swelling of the face, nasal obstruction, black eschars on the nasal bridge or palate, fever, chest pain, respiratory distress, and neurological symptoms in advanced cases. With its malignant character, early diagnosis by clinical evaluation, imaging, and laboratory examination is necessary to enhance the survival rate.

An increased prevalence of immunocompromised diseases, such as diabetes, cancer, and organ transplantation, is a significant growth driver in the mucormycosis market. Uncontrolled diabetes, especially in developing areas, makes an individual more prone to infection owing to elevated levels of blood glucose that provide optimal conditions for growth of the fungi. The uptick in the number of cases of COVID-19 and use of corticosteroids therein has also prompted a sudden upsurge in mucormycosis infections, further increasing the patient base. The increasing incidence of hematological malignancies and extended neutropenia also increases the risk, which is the driving factor in expanding the market. Improved treatment outcomes following developments in antifungal therapies, including liposomal amphotericin B, posaconazole, and isavuconazole, have brought significant efficacy with diminished toxicity. The rising use of combination antifungal therapy and surgical debridement to eliminate necrotic tissue has also enhanced the treatment practice. Moreover, increasing government efforts for awareness and better early detection are fueling the growth of the market. Rising demand for innovative therapeutics, better diagnostic methodologies, and in-hospital treatment approaches, and continuous research activities for next-generation antifungals are set to generate promising opportunities for growth in the market over the forecast period.

IMARC Group's new report provides an exhaustive analysis of the mucormycosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, Asia Pacific has the largest patient pool for mucormycosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mucormycosis market in any manner.

Recent Developments:

• In May 2023, significant advancements in mucormycosis management were reported, including the development of Mucorales-specific polymerase chain reaction (PCR) assays, which have enhanced early detection of mucormycosis. These assays, particularly quantitative PCR (qPCR) tests, have demonstrated good sensitivity and specificity, enabling prompt diagnosis and timely initiation of treatment.

Key Highlights:

• The disease remains rare worldwide, with incidence rates ranging from 0.02 to 9.5 cases per 100,000 individuals.
• India reports significantly higher cases, with an estimated prevalence of 0.14 per 1,000 individuals, making it one of the most affected regions.
• Fatality rates range between 28% and 52%, influenced by factors such as immune status and the extent of infection.
• Individuals with uncontrolled diabetes, weakened immunity, or those undergoing immunosuppressive treatments are at heightened risk.
• A spike in cases was observed during the COVID-19 pandemic, particularly in India, due to steroid use and pre-existing diabetes.

Drugs:

Cresemba (Isavuconazonium), marketed by Basilea Pharmaceutica, is an antifungal prodrug indicated for the treatment of mucormycosis. It metabolizes to isavuconazole, interfering with ergosterol biosynthesis, destabilizing fungal cell membranes. With extended-spectrum coverage and good tolerability, Cresemba represents a valuable therapy option for immunocompromised patients, especially those with amphotericin B intolerance.

SCY-247, created by SCYNEXIS, is a first-in-class antifungal candidate in Phase 1 development for mucormycosis. As a next-generation triterpenoid antifungal, SCY-247 acts on fungal cell membrane integrity, providing potential efficacy against resistant isolates. Its unique mechanism has the goal of enhancing treatment efficacy for life-threatening mucormycosis infections.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mucormycosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mucormycosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mucormycosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the mucormycosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the mucormycosis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the mucormycosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035) of mucormycosis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of mucormycosis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of mucormycosis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035) with mucormycosis across the seven major markets?
• What is the size of the mucormycosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of mucormycosis?
• What will be the growth rate of patients across the seven major markets?

Mucormycosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for mucormycosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mucormycosis market?
• What are the key regulatory events related to the mucormycosis market?
• What is the structure of clinical trial landscape by status related to the mucormycosis market?
• What is the structure of clinical trial landscape by phase related to the mucormycosis market?
• What is the structure of clinical trial landscape by route of administration related to the mucormycosis market?